Dafinchi AI

Tarsus Pharmaceuticals, Inc.

TARS

Healthcare

1w

Financial Performance Summary

Approximately 91,000 bottles were dispensed to patients, slightly above the top end of guidance.
Cash and cash equivalents stood at approximately $381 million at quarter end.
Gross margins remained strong and flat at 93%, with gross-to-net discount around 45%, improving sequentially due to reduced patient copays.
R&D expenses increased by $3.3 million primarily due to the TP-04 program and other development activities.
SG&A expenses increased by approximately $44 million year-over-year, driven by sales and marketing costs including DTC advertising and a larger sales force.
Tarsus reported record-breaking Q2 2025 net sales of $102.7 million for XDEMVY, marking the strongest quarter to date.

VCYT

Healthcare

1w

Financial Performance Summary

Adjusted EBITDA was $35.8 million or 27.5% of revenue, exceeding expectations and validating the company's sustained 25% adjusted EBITDA goal.
Cash from operations was $33.6 million, with cash and cash equivalents ending at $320.7 million.
GAAP net loss was $1 million, impacted by $20.5 million of noncash impairments related to Veracyte SAS.
Non-GAAP gross margin was 71.5%, with testing gross margin at 73.9%, slightly lower than prior year due to prior period cash collections.
Testing volume increased 15% to approximately 44,950 tests, with Decipher and Afirma revenue growing 24% and 5%, respectively.
Veracyte reported Q2 2025 revenue of $130.2 million, a 14% year-over-year increase driven by testing revenue growth of 14%.

Collegium Pharmaceutical, Inc.

COLL

Healthcare

1w

Financial Performance Summary

Adjusted EBITDA grew 9% year-over-year to $105.1 million, while GAAP net income was $12 million compared to $19.6 million in the prior year period.
Collegium Pharmaceuticals reported record quarterly revenue of $188 million, a 29% increase year-over-year, driven by strong performance across its portfolio including Jornay PM and the pain portfolio.
GAAP operating expenses increased 69% year-over-year, and non-GAAP adjusted operating expenses increased 104%, reflecting investments in Jornay commercialization.
Jornay PM generated record quarterly revenues of $32.6 million with prescriptions growing 23% year-over-year.
Operating cash flow was strong at $72.4 million, with $222 million in cash and equivalents at quarter-end.
The pain portfolio achieved record quarterly revenue of $155.4 million, up 7% year-over-year, with all three core pain medicines showing growth.

Orthofix Medical Inc.

OFIX

Healthcare

2w

Financial Performance Summary

Bone Growth Therapies (BGT) net sales reached $62.6 million, growing 6%, with fracture growth at 7%.
Global Orthopedics grew 5% to $33.3 million, led by 28% growth in the U.S. due to new product launches.
Global Spinal Implants, Biologics and Enabling Technologies net sales were $104.8 million, growing 2% year-over-year.
Orthofix reported second quarter 2025 pro forma net sales of $200.7 million, representing 4% year-over-year constant currency growth.
Positive free cash flow of $4.5 million was generated in Q2, with total cash balance increasing to $68.7 million.
Pro forma non-GAAP adjusted EBITDA was $20.6 million or 10.3% of net sales, expanding margin by about 190 basis points year-over-year.
Pro forma non-GAAP adjusted gross margin improved to 72.7%, up approximately 140 basis points from Q2 2024.
USA Spinal Fixation net sales grew 5.4% with a 7% increase in procedure volume, despite a price decrease at a major account.

Repligen Corporation

RGEN

Healthcare

3w

Financial Performance Summary

Acquisitions and foreign currency each contributed approximately 2 points to reported growth.
Adjusted EBITDA margin was 17.6%, flat year-over-year; adjusted net income was $21 million, down $1 million year-over-year.
Adjusted fully diluted EPS was $0.37, down 6% year-over-year, impacted by last year's high-margin COVID business.
Adjusted income from operations was $22 million, up 8% year-over-year, with adjusted operating margin at 12%, down 80 basis points due to COVID and mix headwinds.
Cash position at quarter end was $709 million, up $12 million sequentially, driven by cash flow from operations.
Geographically, North America represented 49% of revenue, Europe 38%, and Asia Pacific and rest of world 13%, with all regions growing mid-teens.
Gross margin was 51.1%, flat year-over-year, with a 3-point mix headwind due to higher resin procurement for OPUS columns.
Repligen reported Q2 2025 revenue of $182 million, a 15% reported increase, 11% organic growth, and 17% organic non-COVID growth.

Cerus Corporation

CERS

Healthcare

1w

Financial Performance Summary

Cerus reported Q2 2025 product revenue of $52.4 million, a 16% year-over-year increase.
First half 2025 product revenue increased 15% to $95.7 million compared to the same period in 2024.
IFC product revenue for Q2 was $5.6 million, up from $2 million in the prior year period.
Net loss was $5.7 million or $0.03 per share, essentially flat year-over-year.
Non-GAAP adjusted EBITDA was positive for the fifth consecutive quarter at $935,000.
North American product revenues increased 17% year-over-year; EMEA product revenues increased 21% year-over-year.
Operating expenses rose to $40.1 million from $33.9 million, driven by higher R&D and SG&A costs.
Product gross profit increased 17% to $29 million with gross margins stable at 55.2%.

AMGN

Healthcare

1w

Financial Performance Summary

15 products achieved double-digit sales growth, highlighting portfolio strength.
Amgen reported Q2 2025 revenues of $9.2 billion, a 9% year-over-year increase driven by 13% volume growth.
Dividend payments increased by 6% to $2.38 per share compared to Q2 2024.
Free cash flow was $1.9 billion, supporting continued innovation investments.
Non-GAAP operating expenses rose 8%, with R&D up 18% reflecting investments in late-stage pipeline programs.
Non-GAAP operating income and expenses (OI&E) improved by $213 million year-over-year due to debt retirement and lower interest expense.